Pediatrix Medical beats Q2 revenue estimates, reaffirms 2026 adjusted EBITDA outlook
MD•Outlook reaffirmed
Pediatrix reaffirmed its 2026 full-year adjusted EBITDA outlook at $280 million to $300 million.
Drivers of the quarter
- Recent acquisitions — The company said revenue growth was driven by recent acquisitions, partially offset by practice dispositions.
- Reimbursement factors — Improved cash collections, favorable payor mix and higher patient acuity, mainly in neonatology, boosted same-unit revenue from net reimbursement-related factors.
- Declining patient volumes — Same-unit revenue attributable to patient volume decreased by 2.1% in Q2, with hospital-based and neonatology services seeing declines.
Key figures and analyst view
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $487.78 million | $478.45 million (7 analysts) |
| Q2 Net Income | $39.84 million | ||
| Q2 Adjusted EBITDA | Slight Beat | $76.43 million | $75.71 million (7 analysts) |
